J&J orthopedics unit draws Apollo interest in potential $20 billion deal: Report

Apollo Global Management, the alternative asset manager, is engaged in substantive negotiations to acquire Johnson & Johnson's orthopedics division in a transformational deal potentially valued near $20 billion. According to reporting from September 11, 2026, the discussions are progressing with an agreement potentially reachable within several weeks, though J&J retains the flexibility to pursue alternative strategic paths including a full spin-off of the business as a standalone entity.

The orthopedics unit under consideration is DePuy Synthes, J&J's well-known hips-and-knees business specializing in surgical devices and orthopedic solutions. The division generated $9.3 billion in revenue, positioning it as a substantial business within J&J's portfolio. However, the unit has faced persistent profitability headwinds coupled with elevated research and development carrying costs, factors that have motivated J&J's strategic review and openness to divestiture or restructuring.

For Apollo, the potential acquisition would represent a marquee entry point into the medical device orthopedics sector, adding a scaled, revenue-generative platform with established market presence and brand recognition to its alternative asset portfolio. The transaction would be consistent with Apollo's recent strategic expansion into healthcare and industrials-focused investments, where the firm has built operational expertise in scaling platform businesses under private ownership.

J&J's exploration of strategic alternatives for the orthopedics business reflects broader portfolio optimization efforts within the pharmaceutical and healthcare conglomerate, particularly as management evaluates which business units align with future growth priorities and capital deployment strategies. The timing and structure of any transaction—whether as an outright sale, spin-off, or hybrid approach—remains fluid pending further due diligence and board evaluation.